We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00 | -2.15% | 45.50 | 45.00 | 46.00 | 46.50 | 44.75 | 46.50 | 4,092,357 | 16:04:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.29 | 129.04M |
TIDMAVCT
Avacta Group PLC
15 January 2018
Hardman Research: Affimer Drug Conjugates a reality
Affimer Drug Conjugates a reality - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry. Avacta has made considerable progress towards its strategic goal to be ready to enter first-in-man Affimer trials by the end of 2019. In addition, Avacta is using external collaborations to expand the opportunities for its Affimer technology. A proof-of-concept study combining its Affimer technology with Glythera's Permalink chemistry to generate Affimer Drug Conjugates has concluded successfully.
Please click here for the full report:
http://www.hardmanandco.com/docs/default-source/company-docs/avacta-documents/15.01.18-affimer-drug-conjugates-a-reality.pdf
Hot Features
Premium
To contact us: Contacts: mh@hardmanandco.com
Hardman & Co Dr Martin dmh@hardmanandco.com
35 New Broad Street Hall gp@hardmanandco.com
London Dr Dorothea www.hardmanandco.com
EC2M 1NH Hill
Follow us on Twitter Dr Gregoire
@HardmanandCo Pave
+44 20 7194
7622
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABGGDBBUBBGIU
(END) Dow Jones Newswires
January 15, 2018 05:58 ET (10:58 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
